Stockscreener 앱 받기
10.08
0.00%
0.00
시간 외 거래:
10.08
전일 마감가:
$10.08
열려 있는:
$10.08
하루 거래량:
531
Relative Volume:
0.01
시가총액:
$220.83M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.50%
6개월 성능:
+20.48%
1년 성능:
+0.00%
1일 변동 폭
$10.08
$10.08
1주일 범위
$10.06
$10.10
52주 변동 폭
$10.00
$10.20
Translational Development Acquisition Corp Stock (TDAC) Company Profile
명칭
Translational Development Acquisition Corp
전화
-
주소
-
TDAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TDAC
Translational Development Acquisition Corp
|
10.08 | 220.83M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
7.47 | 2.19B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.15 | 697.50M | 0 | 16.92M | -1.35M | 0.29 |
|
GATE
Marblegate Acquisition Corp
|
19.61 | 533.61M | 0 | -3.58M | -1.81M | -0.30 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.67 | 460.06M | 0 | 1.30M | 0 | 0.0301 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.12 | 451.52M | 0 | 0 | 0 | 0.00 |
Translational Development Acquisition Corp Stock (TDAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-21 | 개시 | Northland Capital | Outperform |
Translational Development Acquisition Corp 주식(TDAC)의 최신 뉴스
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - Yahoo Finance
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Major SPAC Update: TDACU Splits Units into Separate Shares & Warrants Trading - Stock Titan
Trident Acquisitions stock hits 52-week high of $10.08 By Investing.com - Investing.com Australia
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
Ocean Biomedical Announces Breakthrough Findings in - GlobeNewswire
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com UK
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - Stock Titan
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - Stock Titan
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
Rapid effects of valproic acid on the fetal brain transcriptome: implications for brain development and autism - Nature
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel - GlobeNewswire
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Research and development center Cambridge, Massachusetts - Bristol Myers Squibb (BMS)
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering and Biotechnology News
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering and Biotechnology News
Pioneering Innovative Drug Development at Cambridge Crossing Facility - Bristol Myers Squibb (BMS)
SSI Strategy and NDA Group Combine to Form Best-in-Class Global Life Sciences Consultancy - Business Wire
FirstEnergy issues earnings report - 69News WFMZ-TV
Spatial Genomics and Transcriptomics Market Size Report, 2032 - Global Market Insights
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure - News-Medical.Net
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
IPO Pricings Archives - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Why Kymab Agreed to be Acquired by Sanofi - Timmerman Report
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
VeriSIM Life Announces Acquisition of Molomics Biotech - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
BioSpace Movers & Shakers, Jan. 21 - BioSpace
Third Rock Ventures Promotes David Kaufman, M.D., Ph.D., to Partner - citybiz
Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing - BioSpace
Research and Development grant cheat sheet - The University of Sydney
Crown Bioscience Unveils New Identity - Business Wire
A red blood cell disease meets a company with a plasma protein heritage - Nature
CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings - Business Wire
BioSpace Movers & Shakers, March 19 - BioSpace
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. - Business Wire
BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More - BioSpace
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio - Business Wire
Translational Development Acquisition Corp (TDAC) 재무 분석
Translational Development Acquisition Corp (TDAC)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.00%
0.00%
자본화:
|
볼륨(24시간):